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626Risk Factors Affecting Outcome of Second HLA-Matched
Sibling Donor Transplantations for Graft Failure
in Severe Acquired Aplastic Anemia
John T. Horan,1 Jeanette Carreras,2 Sergey Tarima,2 Bruce M. Camitta,3 Robert Peter Gale,4
Gregory A. Hale,5 Wolfgang Hinterberger,6 Judith Marsh,7 Jakob R. Passweg,8
Mark C. Walters,9 Mary Eapen2We examined transplantation outcomes after a second HLA-matched sibling transplantation for primary
(16%) or secondary (84%) graft failure in 166 patients with severe acquired aplastic anemia (AA). Two-thirds
of these patients has a performance score\90. Inmost cases (88%), the same donorwas used for both trans-
plants, for both transplantations, and 84% of the second transplantations used bone marrow grafts. We iden-
tified 2 prognostic factors: intertransplantation interval (surrogate for primary graft failure and early
secondary graft failure) and performance status. Shorter intertransplantation interval (# 3 months) and
poor performance score (\ 90) at second transplantation were associated with high mortality. In patients
with a performance score of 90% to 100%, the 8-year probability of overall survival (OS) after second trans-
plantation# 3 and. 3 months from first transplantation was 56% and 76%, respectively. The corresponding
probabilities in patients with lower performance scores were 33% and 61%. The predominant cause of failure
after second transplantation was nonengraftment (in 72 of 166 patients), most commonly in patients with pri-
mary or early secondary graft failure (51 of 72; 71%). Our data indicate that novel approaches, including con-
ditioning regimens with greater immunosuppression, should be explored for these patients.
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HLA-matched sibling bone marrow transplanta-
tion (BMT) is an effective treatment for acquired se-
vere aplastic anemia (SAA), particularly in children
and young adults [1-3]. Despite significant improve-
ments in overall survival (OS) over the last 20 years1Blood and Marrow Transplant Program, Emory Univer-
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6/j.bbmt.2009.01.023[2,4,5], the rate of graft failure has not changed
significantly, remaining approximately 10% [5-7].
Many patients with graft failure undergo a second
transplantation with a graft from either the initial do-
nor or a different donor [6,8,9]. We investigated the
factors affecting outcome in 166 patients undergoing
a second HLA-matched sibling transplantation for
primary or secondary graft failure after an initial
HLA-matched sibling transplantation.PATIENTS, MATERIALS, AND METHODS
Patients
Data on 166 patients with SAA undergoing a sec-
ond HLA-matched sibling transplantation between
1986 and 2004 were obtained from the Center for In-
ternational Blood and Marrow Transplant Research,
Medical College of Wisconsin. All of the patients re-
ceived a BM graft from an HLA-matched sibling for
their first transplantation. Six patients who received
peripheral blood progenitor cells (PBPCs) for their
first transplantation were excluded. The Medical
College of Wisconsin’s Institutional Review Board
approved the study design.
Biol Blood Marrow Transplant 15:626-631, 2009 627Second Transplantation for SAAStudy Endpoints
Neutrophil recovery was defined as achieving an
absolute neutrophil count (ANC) $ 0.5  109/L for 3
consecutive days and a platelet count$ 20 109/L un-
supported for 7 days. Acute and chronic graft-versus-
host disease (aGVHD, cGVHD) was diagnosed and
graded by the transplantation centers using standard
criteria [10]. Primary graft failure was defined as failure
to achieve an ANC $ 0.5  109/L for 3 consecutive
days; secondary graft failure was defined as a sustained
decline in ANC after initial recovery. Death from any
cause was considered an event, and all surviving
patients were censored at last follow-up.
Statistical Methods
The probabilities of neutrophil and platelet recov-
ery, aGVHD, and cGVHD were calculated using the
cumulative incidence estimator, with death without
the event as the competing event [11]. The probabili-
ties of earlymortality (day 100) andOSwere calculated
using the Kaplan-Meier estimator [12]. The 95% con-
fidence interval (CI) was calculated using log-transfor-
mation. Regression models for neutrophil and platelet
recovery and early mortality were constructed using
the pseudovalue method [13], and those for overall
mortality were constructed using the Cox regression
method [12]. All models were constructed using step-
wise forward selection, with a P value# .05 indicating
statistical significance. The variables considered in the
regressionmodels are listed inTable 1.Only those var-
iables that attained a P value# .05 duringmodel build-
ing were retained in the final model. We tested for an
effect of transplantation center and found none [14].
All P values are 2-sided, and all analyses were done us-
ing SAS version 9.1 (SAS Institute, Cary, NC).RESULTS
Table 1 summarizes patient, disease, and trans-
plantation characteristics for the first and second
transplantations, as well as for the 23 third transplanta-
tions. All patients received BMgrafts for the first trans-
plantation; 84% of patients received BM grafts and
16% received PBPCs for the second transplantation.
The median time between the first and second trans-
plantations was 7 months (range, 1 to 114 months);
2/3 of the second transplantations occurred within
1 year from the first transplantation.
Hematopoietic Recovery
The probabilities of neutrophil recovery at day 28
and of platelet recovery at day 60 after second trans-
plantation were 63% (95% CI 5 55% to 70%) and
62% (95%CI5 58% to 73%), respectively (Figure 1).
Thirty-six patients failed to achieve neutrophil recov-ery, and 54 patients failed to achieve platelet recovery.
In addition, 18 patients experienced graft failure after
initial hematopoietic recovery; in 14 of these patients,
graft failure occurred within 12 months after second
transplantation, and in the remaining 4 patients, graft
failure occurred between 13 and 37 months. In multi-
variate analysis, neutrophil recovery after second
transplantation was more likely with PBPCs (odds ra-
tio [OR] 5 12.91; 95% CI 5 2.65 to 62.83; P 5 .002)
and when the indication for transplantation was sec-
ondary graft failure after the first transplantation
(OR5 4.39; 95% CI5 1.60 to 12.08; P5 .004). Nei-
ther performance score (OR5 1.68; 95%CI5 0.84 to
3.37; P 5 .144) nor conditioning regimen (cyclophos-
phamide [Cy] with limited field irradiation vs Cy plus
antithymocyte globulin [ATG]: OR5 0.56, 95%CI5
0.24 to 1.31, P 5 .178; other regimens vs Cy plus
ATG: OR 5 0.99, 95% CI 5 0.49 to 2.03, P 5 .982)
was associated with neutrophil recovery.
Platelet recovery also was more likely after trans-
plantation with PBPCs (OR 5 11.25; 95% CI 5
2.30 to 54.99; P 5 .003), when the indication for sec-
ond transplantation was secondary graft failure
(OR 5 8.80; 95% CI 5 2.63 to 29.43; P\ .001), and
when the patient’s performance score was 90 to 100
(OR5 3.60; 95%CI5 1.47 to 8.81; P5 .005). Platelet
recovery also was associated with the conditioning reg-
imen for the second transplantation; recovery was less
likely in those receiving an irradiation-containing con-
ditioning regimen (OR5 0.22; 95%CI5 0.08 to 0.60;
P 5 .003).
Graft-versus-Host Disease
The probability of grade II-IV aGVHDby day 100
posttransplantation was 9% (95% CI 5 5% to 14%).
The 8-year probability of cGVHD was 16% (95%
CI 5 10% to 22%). The rate of cGVHD was higher
after transplantation with PBPCs compared with BM
(26% vs 14%), but this difference did not achieve sta-
tistical significance (P 5 .274).
Overall Survival
With a median follow-up of. 8 years after second
transplantation, 97 of 166 patients are alive at the time
of this writing. Early (day 100) mortality rates were
high (30% [49/166]); primary graft failure (n 5 24)
was the most frequent cause of death during this
period. Fewer deaths (n 5 20) occurred beyond
100 days. In multivariate analysis, the performance
score at second transplantation and the intertransplan-
tation interval were independent predictors of OS. In
patients requiring a second transplantation within 3
months of the first transplantation because of primary
or early secondary graft failure, the relative risk (RR) of
early mortality was 3.12 (95% CI 5 1.47 to 6.62; P 5
.003), and the RR of overall mortality was 2.15 (95%
Table 1. Patient, Disease, and Transplant Characteristics
First Transplantation, Second Transplantation, Third Transplantation,
Variable n (%) n (%) n (%)
Number of patients 166 166 23
Age at transplantation, years
# 10 64 (39) 56 (34) 11 (48)
11-20 49 (29) 52 (31) 3 (13)
21-30 37 (22) 41 (25) 6 (26)
$ 31 16 (10) 17 (10) 3 (13)
Male sex 97 (58) 97 (58) 17 (74)
Karnofsky score pretransplantation
< 90 82 (50) 111 (67) 15 (65)
$ 90 83 (50) 54 (33) 8 (35)
Unknown 1 1 0
Reason for second
and third transplantations
Primary graft failure 26 (16) 5 (22)
Secondary graft failure 140 (84) 18 (78)
Intertransplantation interval
(first to second transplantation)
NA NA
# 3 months 47 (28)
> 3 months 119 (72)
Conditioning regimen
Cy + ATG 36 (21) 73 (44) 7 (30)
Cy + TBI/TLI/TAI ± other 21 (12) 31 (19) 3 (13)
Cy alone 88 (53) 8 (5) 0
Busulfan + Cy 17 (10) 16 (10) 2 (9)
Other 4 (1) 32 (19) 6 (26)
None* 0 12 (7) 5 (22)
GVHD prophylaxis
Cyclosporine + methotrexate ± other 134 (80) 104 (63) 0
Cyclopsorine ± other 27 (16) 54 (32) 6 (26)
Methotrexate ± other 3 (2) 1 (1) 13 (57)
Tacrolimus ± other 1 (1) 3 (2) 1 (4)
None 4 (2) 3 (13)
Nucleated cells
infused,  108/kg
< 3.0 42 (26) 39 (25) 8 (38)
$ 3.0 120 (74) 114 (75) 13 (62)
Unknown 4 13 2
Donor type N/A
Same related
donor as for first transplant
146 (88) 21 (91)
Different related donor 20 (12) 2 (9)
Unrelated donor 0 0
Donor–recipient sex match
Male donor/male recipient 54 (33) 52 (31) 9 (41)
Male donor/female recipient 45 (27) 46 (28) 0
Female donor/male recipient 43 (26) 45 (27) 8 (36)
Female donor/female recipient 24 (14) 23 (14) 5 (23)
Missing 0 0 1
Graft type
BM 166 (100) 140 (84) 16 (70)
PBPCs 26 (16) 7 (30)
Year of transplantation
1986-1989 47 (28) 42 (25) 7 (30)
1990-1993 46 (28) 41 (25) 5 (22)
1994-1997 40 (24) 36 (22) 1 (4)
1998-2002 33 (20) 41 (25) 8 (35)
2003-2004 0 6 (3) 2 (9)
Median follow-up
of survivors after
second transplantation, months
97 (6-215) 122 (19-188)
NA, indicates not applicable; Cy, cyclophosphamide; TAI, total abdominal irradiation; PBPCs, peripheral blood progenitor cells; BM, bone marrow;
GVHD, graft-versus-host disease; TBI, total body irradiation; TLI, total lymphoid irradiation.
*Twelve patients received a second transplantation without conditioning. Four of these 12 patients underwent transplantation for primary graft failure;
their intertransplantation intervals were 0.69, 1.74, 2.60, and 6.88 months. The remaining 8 patients underwent transplantation for secondary graft fail-
ure; their intertransplantation intervals were 1.25, 1.38, 2.37, 5.76, 8.78, 9.61, 18.68, and 29.90 months. Five patients underwent a third transplantation
without conditioning. Two of these 5 patients underwent transplantation for primary graft failure; their intertransplantation intervals were 0.86 and 4.64
months. The remaining 3 patients underwent transplantation for secondary graft failure; their intertransplantation intervals were 1.41, 4.67, and 26.74
months.
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Figure 1. Cumulative incidence of neutrophil and platelet recovery
after second HLA-matched sibling donor transplantation for graft
failure.
Biol Blood Marrow Transplant 15:626-631, 2009 629Second Transplantation for SAACI5 1.32 to 3.51; P5 .002). In patients with a perfor-
mance score\ 90, the RR of early mortality was 5.81
(95%CI5 2.12 to 16.13; P\ .001), and that of overall
mortality was 1.88 (95% CI5 1.05 to 3.38; P5 .033).
Considering the influence of intertransplantation
interval and performance status together, OS was
highest in second transplantations done after 3 months
from first transplantations and in patients with a per-
formance score of 90 to 100. In patients with such
a performance score, the 8-year probability of OS
was 56% when the interval between the first and sec-
ond transplantations was\ 3 months and 76% when
this interval was . 3 months (Figure 2). The corre-
sponding probabilities in patients with lower
performance scores were 33% and 61%. Two trans-
plantation strategies, using a different sibling donor
(RR 5 1.22; P 5 .558) and using PBPCs (RR 5
0.56; P 5 .159), were not associated with overall mor-
tality. We found no association between the type of
conditioning regimen and overall mortality (Cy withP
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Figure 2. Overall survival after second HLA-matched sibling donor
transplantation for graft failure in SAA by time between first to second
transplantation and Karnofsky performance score. Eight-year probabil-
ity of overall survival in patients with a performance score of 90 to
100 and an intertransplantation interval . 3 months (.. ; 76% [95%
CI 5 62% to 88%]); in patients with a performance score\ 90 and an
intertransplantation interval . 3 months (– – – –; 61% [95% CI 5
50% to 72%]); in patients with a performance score of 90 to 100 and
an intertransplantation interval\ 3 months (- - - - -; 56% [95% CI 5
24% to 85&]); and in patients with a performance score\90 and an in-
tertransplantation interval\3 months (———; 33% [95% CI5 19% to
49%]).limited-field irradiation vs Cy plus ATG: RR 5 1.31,
95% CI 5 0.70 to 2.45, P 5 .394; and other regimens
vs Cy plus ATG: RR5 1.00, 95%CI5 0.58 to 1.72, P
5 .993). Twenty-three patients underwent a third
transplantation for secondary graft failure after the
second transplantation (Table 1). Of these 23 patients,
15 achieved sustained hematopoietic recovery and 11
were alive at last follow-up. Table 2 presents the causes
of death for the entire cohort; as shown, the 2 most
common causes were graft failure and infection.DISCUSSION
In this study, we identified 2 factors associated with
survival after second HLA-matched sibling transplan-
tation for SAA: intertransplantation interval of . 3
months and good performance score (90 to 100) at
second transplantation. Intertransplantation interval
serves as a surrogate for the type and rapidity of graft
failure, allowing cases of primary graft failure or early
secondary graft failure to be distinguished from cases
of late secondary graft failure. When the cohort was
stratified by intertransplantation interval and perfor-
mance score, 3 prognostic groups emerged. Patients
with an intertransplantation interval . 3 months and
a good performance score did well in the long term,
with an estimated 8-year survival of 76%, whereas
those with an intertransplantation interval\3 months
and a performance score\ 90 fared poorly, with an
estimated 8-year survival of 33%. Patients with
a long intertransplantation interval, but a suboptimal
performance score or a good performance score, but
a short intertransplantation interval had an intermedi-
ate outcome (estimated 8-year survival rate of 61% and
56%, respectively). Our observations are limited to
patients who failed their first transplantation and un-
derwent a second transplantation. Only 1/3 of patients
with primary or secondary graft failure after first trans-
plantation for SAA undergo a second transplantation
(Unpublished data, Center for International Blood
and Marrow Transplant Research, January 2009).
The decision to offer a second transplantation is at
the discretion of the treating physician, and the ratio-
nale for not offering a second transplantation is not
collected by this registry. This represents a limitationTable 2. Causes of Death in 69 Patients Evaluated
Cause of Death n (%)
Graft failure 21 (31)
Infection 14 (20)
Interstitial pneumonia 5 (7)
GVHD 7 (10)
Primary disease 6 (9)
Organ failure 6 (9)
Hemorrhage 3 (4)
Other, not specified 7 (10)
630 Biol Blood Marrow Transplant 15:626-631, 2009J. T. Horan et al.when analyzing data collected by an observational da-
tabase.
Our finding of an association between a longer
intertransplantation interval and increased survival
substantiates the findings of 3 previous studies
[8,9,15]. Two of those studies demonstrated an asso-
ciation between a longer intertransplantation interval
and survival, and the other demonstrated an associa-
tion between secondary graft failure and survival.
(Most of the patients in our analysis with secondary
graft failure also had a long intertransplantation in-
terval.) That a short intertransplantation interval is
disadvantageous is not surprising; performing a sec-
ond transplantation too soon after the first allows in-
sufficient time to recover from the toxicity or the
myelosuppressive effects of conditioning, increasing
the risk of death from infection or organ injury.
Moreover, the rapidity of graft failure may reflect
the potency of the barrier to sustained engraftment
with the conditioning regimens used during the
study era. Most of our patients received Cy with or
without ATG and limited-field irradiation. Although
this regimen is effective for first transplantations,
regimens with greater immunosuppressive potency
may be required for sustained engraftment in pa-
tients requiring a second transplantation.
The type of GVHD prophylaxis had no noticeable
effect on outcome. This finding runs counter to results
reported by Stucki et al. [9]. In that study, which exam-
ined transplantations between 1970 and 1997, higher
survival was associated with the use of a cyclosporine
and methotrexate (CsA/MTX) combination prophy-
laxis regimen as opposed to an MTX alone regimen.
The lack of effect of GVHD prophylaxis in our study
can best be explained by the fact that virtually all of
the patients who underwent transplantation in this
more recent period received calcineurin inhibitor–
based GVHD prophylaxis.
We found no relationships between the various
conditioning regimens used and survival. The intensity
of the regimens used was fairly similar, which may
explain our inability to identify regimens that may
have enhanced hematopoietic recovery, particularly
in those with primary or early secondary graft failure.
The observed negative association between irradia-
tion-based conditioning regimens and platelet recov-
ery is difficult to account for, because the use of
irradiation has been associated with sustained engraft-
ment in previous studies [6].
Using a different sibling donor for the second
transplantation conferred no detectable advantage in
our analysis. Similarly, even though the use of PBPC
grafts was associated with improved myeloid recovery
(both neutrophils and platelets), it had no measurable
effect on survival. A recent study from the Center for
International Blood and Marrow Transplant Research
comparing PBPC and BM grafts in first transplanta-tions in patients with SAA found a higher rate of
cGVHD and lower survival after PBPC transplanta-
tions in younger patients [16]. In the absence of
a graft-versus-tumor effect for SAA, the burden of
morbidity and late mortality associated with cGVHD
must be weighed against any potential benefit derived
from faster hematopoietic recovery [17,18].
New approaches are needed for patients undergo-
ing a second transplantation for SAA, particularly
those with primary or early secondary graft failure
and a poor performance score, in whom the prognosis
is dismal. Efforts should focus on preventing graft fail-
ure after the first transplantation by optimizing the
conditioning regimen (Cy and ATG) and GVHD pro-
phylaxis with a calcinuerin inhibitor and a short course
of MTX. Transplantation of PBPCs results in faster
hematopoietic recovery but does not translate into
a survival advantage. Approximately 45% of our pa-
tients received CsA and ATG, and the rest received
various other conditioning regimens. Given our rela-
tively small study population (166 patients), we were
unable to identify an optimal regimen that may ensure
sustained hematopoietic recovery. Nevertheless, Cy
and ATG, the most frequently used regimen, was
successful in several patients. Although conditioning
regimens with greater immunosuppression or myeloa-
blation merit consideration in patients with early graft
failure, the risks and benefits of such regimens must be
carefully weighed.ACKNOWLEDGEMENTS
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